Yizhi Jiang

机构：Oklahoma Medical Research Foundation, Tongji Hospital, Huazhong University of Science and Technology · ORCID：0000-0002-4812-2547

发表论文 38 篇 · 总被引 484 次 · h-index 10

代表论文

• Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives (2024 · International Journal of Molecular Sciences · 被引 107)
• Kupffer cell receptor CLEC4F is important for the destruction of desialylated platelets in mice (2021 · Cell Death and Differentiation · 被引 81)
• Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis (2021 · Thrombosis Research · 被引 41)
• Slc35a1 deficiency causes thrombocytopenia due to impaired megakaryocytopoiesis and excessive platelet clearance in the liver (2020 · Haematologica · 被引 30)
• Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs (2024 · Pharmaceuticals · 被引 21)
• Safety and efficacy of an anti–human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models (2023 · Blood · 被引 19)